

# WOAH Reference Laboratory Reports Activities 2022

## Activities in 2022

This report has been submitted : 5 mai 2023 09:53

### Laboratory Information

<b>Name of disease (or topic) for which you are a designated WOA Reference Laboratory:</b>	Infection with ranavirus
<b>Address of laboratory:</b>	CSIRO-ACDP, Private Bag 24
<b>Tel.:</b>	436694252
<b>E-mail address:</b>	Nick.Moody@csiro.au
<b>Website:</b>	
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Prof. Trevor Drew - Director
<b>Name (including Title and Position) of WOA Reference Expert:</b>	Nick Moody, Research Group Leader
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental

### TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
Direct diagnostic tests		Nationally	Internationally
CSIRO Ranavirus qPCR	No	16	

### TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

No

4. Did your laboratory produce vaccines?

Not applicable

5. Did your laboratory supply vaccines to WOA Members?

Not applicable

### ***TOR3: NEW PROCEDURES***

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA Standards for the designated pathogen or disease?

No

### ***TOR4: DIAGNOSTIC TESTING FACILITIES***

10. Did your laboratory carry out diagnostic testing for other WOA Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

No

### ***TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES***

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

No

### ***TOR6: EPIZOOLOGICAL DATA***

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

b) International conferences:

c) National conferences:

d) Other (Provide website address or link to appropriate information):

## **TOR7: SCIENTIFIC AND TECHNICAL TRAINING**

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

No

## **TOR8: QUALITY ASSURANCE**

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	pdf	NATA ISO 17025 SEP 2022.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Ranavirus-specific assays are not within the scope of accreditation	National Association of Testing Authorities (NATA, ILAC affiliated)

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory has a dedicated Biorisk Management Team (14 Members) who provide specialist advice, monitor and improve Biosafety, Biosecurity and Biocontainment activities and perform maintenance on Biocontainment systems. The team uses a risk analysis approach to management of biological risks for biosafety and biosecurity to inform and determine the policy and procedures that in turn give confidence that the laboratory procedures for each of the biological materials handled by the laboratory pose negligible danger to Australia's animal and human populations. 261 Policies and procedures are contained in the annually reviewed ACDP Biorisk Manual consisting of various sections as follows. Section 1 Administration Section 2 PC2 Procedures and Policies Section 3 PC3 Procedures and Policies Section 4 PC4 Procedures and Policies Section 5 Large Animal Facility (LAF) Procedures and Policies Section 6 Personnel and Procedural Controls Section 7 Transport and Storage of Biological Material Section 8 Movement of Material, Equipment and Waste

Section 9 Engineering Procedures and Policies Section 10 Microbiological Incident Response Procedures and Policies Section 11 Laboratory Services Group Section 12 Containment Services Group The successful ACDP biological risk management system has clear and unequivocal commitment by laboratory management, who ensure that roles, responsibilities, resources and authorities related to biological risk management are defined, documented, and communicated to those who manage, perform, and verify work associated with biological agents and toxins in the laboratory. The Biorisk Management Team are audited over 3 days every 6 months by an external security assessment team to provide an independent review of elements affecting ACDP's microbiological and physical security operations and to advise CSIRO senior executive management of any areas of concern or risk. The laboratory is aspiring to become accredited to ISO 35001:2019 Biorisk management for laboratories and other related organisations.

## **TOR9: SCIENTIFIC MEETINGS**

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

No

## **TOR10: NETWORK WITH WOA REFERENCE LABORATORIES**

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Not applicable (only WOA Reference Laboratory designated for the disease)

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

Not applicable (Only WOA Reference Laboratory designated for the disease)

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen?

Not applicable (Only WOA Reference Laboratory designated for the disease)

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (Only WOA Reference Laboratory designated for the disease)

## **TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING**

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen?

No

## **TOR12: EXPERT CONSULTANTS**

28. Did your laboratory place expert consultants at the disposal of WOA?

No

29. Additional comments regarding your report:

Yes

*ACDP-AFDL employed a post-doctoral fellow in August 2022 whose activities will include clarifying the relationships of Ranavirus*

*isolates, assay validation and publication. The post-doctoral fellow was employed to support the activities of the Reference Laboratory.*